Nasdaq:TLSI
TriSalus Life Sciences, Inc.
TriSalus Life Sciences leverages proprietary drug delivery systems and medical devices to capture market share in high-growth interventional medicine sectors.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock given its recent double-digit revenue growth trajectory and proprietary technology moat that could eventually lead to sustainable profitability if market penetration accelerates. The company's focus on high-value interventional procedures offers significant upside potential as it expands its addressable market in pain management and vascular care.
Bear Case
The investment case is severely weakened by a negative shareholder equity of $25.9M and a massive retained earnings deficit of nearly $280M, suggesting the company has burned through substantial capital without achieving profitability. Continued reliance on equity dilution to fund operations poses a long-term threat to existing shareholders if operational efficiency cannot be improved quickly.
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences develops proprietary drug delivery technologies and advanced medical devices, primarily serving hospitals and healthcare providers. The company focuses on innovative solutions such as the TriLok device for pain management and specialized catheters, aiming to address unmet needs in interventional medicine. Revenue growth has been significant recently, though profitability remains a critical challenge.
Analysis
Management Discussion
While TriSalus achieved a 58% year-over-year revenue increase from $18.5M to $29.4M in 2024, the company continues to report substantial net losses of $30M and negative operating cash flow of $40.8M. The management's ability to extend their runway is heavily dependent on external capital raising, evidenced by $37.9M in financing cash flows and $15.5M in share issuances during the period.
Industry Overview
The medical device industry is characterized by high regulatory barriers, intense competition from established giants, and a shift towards value-based care models that favor cost-effective innovations. Companies in this sector must continuously innovate to maintain market share while navigating complex reimbursement landscapes and supply chain complexities.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $18.5M | $29.4M |
| Cost of Revenue | $0 | $2.6M | $4.1M |
| Gross Profit | $0 | $15.9M | $25.3M |
| Operating Expenses | $2.7M | $70.1M | $61.5M |
| Operating Income | $-2.7M | $-54.1M | $-36.2M |
| R&D | — | $29.5M | $17.7M |
| G&A | $2.7M | $23.5M | $18.0M |
| Marketing | — | $17.0M | $25.8M |
| Stock-Based Comp | — | $1.4M | $5.4M |
| D&A | — | $702.0K | $744.0K |
| Depreciation | — | $684.0K | $700.0K |
| Amortization | — | $18.0K | — |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $8.9M | $-4.9M | $6.1M |
| Interest Expense | — | $16.0K | — |
| Interest Income | $3.0M | $431.0K | $404.0K |
| Pre-Tax Income | $6.1M | $-59.0M | $-30.0M |
| Income Tax | $570.9K | $9.0K | $6.0K |
| Continuing Ops | $5.5M | $-59.0M | $-30.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $5.5M | $-59.0M | $-30.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $5.5M | $-59.0M | $-30.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $359.9K | $20.9M | $20.7M |
| Cash & Equivalents | $153.6K | $11.8M | $8.5M |
| Accounts Receivable | — | $3.6M | $5.1M |
| Inventory | — | $2.5M | $4.0M |
| Other Current Assets | $206.3K | $3.0M | $3.0M |
| Long-Term Assets | $19.8M | $4.9M | $3.3M |
| Operating Leases | — | $1.2M | $1.2M |
| Other LT Assets | — | $3.7M | $2.1M |
| Total Assets | $20.2M | $25.7M | $24.0M |
| Current Liabilities | $2.5M | $14.7M | $10.2M |
| Current Leases | — | $275.0K | $136.0K |
| Taxes Payable | $27.9K | $31.0K | $34.0K |
| Other Current Liab | $2.5M | $3.8M | $2.7M |
| Long-Term Liabilities | $11.2M | $37.0M | $39.6M |
| Long-Term Debt | — | — | $22.1M |
| LT Operating Leases | — | $1.2M | $1.3M |
| Other LT Liab | — | $35.8M | $16.2M |
| Total Liabilities | $13.7M | $51.7M | $49.9M |
| Shareholders' Equity | $6.5M | $-25.9M | $-25.9M |
| Paid-In Capital | — | $222.4M | $253.7M |
| Retained Earnings | $-13.3M | $-248.4M | $-279.5M |
| Total L&E | $20.2M | $25.7M | $24.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $5.5M | $-59.0M | $-30.0M |
| Non-Cash Adjustments | $-8.5M | $4.4M | $-11.0M |
| Working Capital Changes | $246.4K | $4.6M | $225.0K |
| Cash from Operations | $-2.7M | $-50.0M | $-40.8M |
| Capital Expenditures | — | $588.0K | $345.0K |
| Cash from Investing | $233.2M | $-2.1M | $-345.0K |
| Share Buybacks | $232.4M | — | — |
| Cash from Financing | $-230.5M | $54.6M | $37.9M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-47.3K | $2.5M | $-3.3M |
| Beginning Cash | $200.9K | $9.7M | $12.1M |
| Ending Cash | $153.6K | $12.1M | $8.9M |
Frequently Asked Questions
How does TriSalus Life Sciences, Inc. make money?
The company's revenue is driven by its core medical device segment featuring the TriLok pain management system, specialized catheter technology for vascular procedures, and associated consumable supplies sold directly to healthcare facilities and distributors.
What are the main risks for TLSI?
The company faces substantial cash burn with negative operating cash flow exceeding $40M, significant accumulated retained earnings deficit indicating historical losses, high general and administrative expenses relative to revenue, and intense competition in the medical device market which could erode margins.
What is TLSI's competitive advantage?
TriSalus possesses strong intellectual property protection through its patented drug delivery mechanisms, a highly skilled engineering team capable of rapid product iteration, and established partnerships with major hospital systems that provide stable long-term revenue streams.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.